This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Blenrep (belantamab mafodotin-blmf)
General Description:
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate used for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) whose disease has progressed despite prior therapy with an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Blenrep targets B-cell maturation antigen (BCMA) expressed on multiple myeloma cells. Once bound, it delivers a cytotoxic agent directly into the tumor cells, leading to apoptosis and cell death. This targeted approach helps reduce damage to healthy tissues while effectively attacking cancer cells.
Disease Indications:
Multiple Myeloma
Manufacturer:
GlaxoSmithKline (GSK)
Usage:
Intravenous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
Package:
• Single-dose vial × 100 mg
Shipping:
Cold Chain Shipping
Blenrep contains temperature-sensitive medicinal ingredients that can be degraded by heat, light, or improper handling. Therefore, it is transported using cold chain delivery, which employs specialized medical couriers with temperature-controlled packaging and vehicles to ensure product integrity.
While cold chain shipping may be more expensive than standard methods, it guarantees that the medicine remains uncompromised and fully effective upon arrival.
How to Access Blenrep (belantamab mafodotin-blmf) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Blenrep (belantamab mafodotin-blmf) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
